Ewha Womans University Seoul Hospital Settles Prostate Cancer PSMA PET/CT Testing System
Jul 11, 2024
Ewha Womans University Seoul Hospital (Hospital Director Joo Woong) successfully settled the test system on the 3rd, achieving 250 cases of 'Ga-68 PSMA-11 PET/CT tests' for prostate cancer patients.
The Ga-68 PSMA PET/CT test is a three-dimensional imaging test that confirms radiation signals from prostate cancer or metastatic cancer cells as images through positron emission tomography (PET/CT) devices, and is a test method proven to be stable and effective in staging, recurrence diagnosis, and evaluation of treatment response for prostate cancer patients. In particular, due to its high sensitivity and specificity, it is very useful not only for diagnosing prostate cancer but also for determining the presence or absence of metastasis.
Since the first test of 'Ga-68 PSMA PET/CT' began at Ewha Womans University Seoul Hospital on November 28 last year, ▲ patients suspected of prostate cancer but difficult to confirm by biopsy ▲ patients suspected of recurrence but difficult to find the exact location of the recurrence lesion can be examined to provide appropriate treatment.
In fact, after prostate cancer surgery, there was a case in which bone metastasis was confirmed after Ga-68 PSMA PET/CT in patients whose PSA levels were suspected to recur due to continuous elevated levels for several months, but whose lesions were not confirmed.
Professor Kim Bum-san (Director of Nuclear Medicine) of the Department of Nuclear Medicine at Ewha Womans University Seoul Hospital said, `Ga-68 PSMA PET/CT, a screening test for treatment, is expected to be more useful at a time when Pluvicto, a therapeutic radioactive drug for patients with metastatic castration-resistant prostate cancer, is expected to be introduced in Korea.'
The Ga-68 PSMA PET/CT test is a three-dimensional imaging test that confirms radiation signals from prostate cancer or metastatic cancer cells as images through positron emission tomography (PET/CT) devices, and is a test method proven to be stable and effective in staging, recurrence diagnosis, and evaluation of treatment response for prostate cancer patients. In particular, due to its high sensitivity and specificity, it is very useful not only for diagnosing prostate cancer but also for determining the presence or absence of metastasis.
Since the first test of 'Ga-68 PSMA PET/CT' began at Ewha Womans University Seoul Hospital on November 28 last year, ▲ patients suspected of prostate cancer but difficult to confirm by biopsy ▲ patients suspected of recurrence but difficult to find the exact location of the recurrence lesion can be examined to provide appropriate treatment.
In fact, after prostate cancer surgery, there was a case in which bone metastasis was confirmed after Ga-68 PSMA PET/CT in patients whose PSA levels were suspected to recur due to continuous elevated levels for several months, but whose lesions were not confirmed.
Professor Kim Bum-san (Director of Nuclear Medicine) of the Department of Nuclear Medicine at Ewha Womans University Seoul Hospital said, `Ga-68 PSMA PET/CT, a screening test for treatment, is expected to be more useful at a time when Pluvicto, a therapeutic radioactive drug for patients with metastatic castration-resistant prostate cancer, is expected to be introduced in Korea.'
|
bellho@sportschosun.com
